Skip to content

Accelerating vaccine development for schistosomiasis japonicum: Surveying public acceptance of the vaccine for schistosomiasis japonicum

Accelerating vaccine development for schistosomiasis japonicum: Surveying public acceptance of the vaccine for schistosomiasis japonicum - Surveying public acceptance of the vaccine for schistosomiasis japonicum

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091771
Enrollment
Unknown
Registered
2024-11-04
Start date
2024-11-04
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schistosomiasis

Interventions

Test group:Educational video intervention

Sponsors

The 920 Hospital of the Chinese People's Liberation Army Joint Logistic Support Force
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Pre-Intervention Study: Individuals aged between 18 and 60, who have household registration in the study area and currently reside in Dali, Yunnan; who can read, listen, and understand Chinese and Mandarin; who have no serious illnesses and voluntarily agree to participate in the study and agree to participate in educational interventions during the study period will be included in this study. Intervention Study: Based on the pre-intervention study, participants who have previously received information related to schistosomiasis. Post-Intervention Study: The inclusion criteria are the same as those for the intervention study.

Exclusion criteria

Exclusion criteria: 1.Pre-Intervention Study: Individuals who have household registration in the study area but have moved out, those who cannot listen to, read, or understand Chinese and Mandarin, or those with severe physical or mental illnesses will be excluded. Intervention Study: Individuals who have not received schistosomiasis education, those with invalid pre-intervention questionnaires, or those unwilling to participate in subsequent studies will be excluded. Post-Intervention Study: The exclusion criteria are the same as those for the intervention study.

Design outcomes

Primary

MeasureTime frame
The acceptance of vaccine;

Countries

China

Contacts

Public ContactWang Sanbing

The 920 Hospital of the Chinese People's Liberation Army Joint Logistic Support Force

dr.qianxuyang@gmail.com+86 131 8742 4131

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026